1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Keratoconjunctivitis Sicca - Pipeline Review, H2 2020, provides an overview of the Keratoconjunctivitis Sicca (Ophthalmology) pipeline landscape.
Keratoconjunctivitis sicca (KCS) or dry eye disease (DED) or dry eye syndrome (DES) is a condition in which a person experience desiccation of the conjunctiva and cornea due to an inadequate tear film. Symptoms include hyperemia, mucoid discharge, ocular irritation, photophobia and blurry vision. Risk factors include age, wearing contact lenses and low levels of vitamin A. Treatment includes artificial tear substitutes, topical anti-inflammatory agents, secretagogues and immunosuppressants.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Keratoconjunctivitis Sicca - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Keratoconjunctivitis Sicca (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Keratoconjunctivitis Sicca (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Keratoconjunctivitis Sicca (Dry Eye) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 17, 31, 12, 1, 43, 6 and 7 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 2 and 1 molecules, respectively.
Keratoconjunctivitis Sicca (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Keratoconjunctivitis Sicca (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Keratoconjunctivitis Sicca (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Keratoconjunctivitis Sicca (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Keratoconjunctivitis Sicca (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Keratoconjunctivitis Sicca (Ophthalmology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Keratoconjunctivitis Sicca (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Keratoconjunctivitis Sicca (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
IntroductionKeratoconjunctivitis Sicca (Dry Eye) - Overview
Keratoconjunctivitis Sicca (Dry Eye) - Therapeutics Development
Keratoconjunctivitis Sicca (Dry Eye) - Therapeutics Assessment
Keratoconjunctivitis Sicca (Dry Eye) - Companies Involved in Therapeutics Development
Keratoconjunctivitis Sicca (Dry Eye) - Drug Profiles
Keratoconjunctivitis Sicca (Dry Eye) - Dormant Projects
Keratoconjunctivitis Sicca (Dry Eye) - Discontinued Products
Keratoconjunctivitis Sicca (Dry Eye) - Product Development Milestones
Appendix
List of Tables
- Number of Products under Development for Keratoconjunctivitis Sicca (Dry Eye), H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by AB2 Bio Ltd, H2 2020
- Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Abilita Bio Inc, H2 2020
- Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Actinobac Biomed Inc, H2 2020
- Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Aerie Pharmaceuticals Inc, H2 2020
- Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Aldeyra Therapeutics Inc, H2 2020
- Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Allegro Ophthalmics LLC, H2 2020
- Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by Allergan Ltd, H2 2020
- Keratoconjunctivitis Sicca (Dry Eye) - Pipeline by OccuRx Pty Ltd, H2 2020
- Keratoconjunctivitis Sicca (Dry Eye) - Dormant Projects, H2 2020
- Keratoconjunctivitis Sicca (Dry Eye) - Discontinued Products, H2 2020
List of Figures
- Number of Products under Development for Keratoconjunctivitis Sicca (Dry Eye), H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Number of Products by Top 10 Targets, H2 2020
- Number of Products by Stage and Top 10 Targets, H2 2020
- Number of Products by Top 10 Mechanism of Actions, H2 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
- Number of Products by Top 10 Routes of Administration, H2 2020
- Number of Products by Stage and Top 10 Routes of Administration, H2 2020
- Number of Products by Top 10 Molecule Types, H2 2020
- Number of Products by Stage and Top 10 Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AB2 Bio Ltd
- Abilita Bio Inc
- Actinobac Biomed Inc
- Aerie Pharmaceuticals Inc
- Aldeyra Therapeutics Inc
- Allegro Ophthalmics LLC
- Allergan Ltd
- Allgenesis Biotherapeutics Inc
- Allosterix Ltd
- Allysta Pharmaceuticals Inc
- Apidel SA
- Ascendia Pharmaceuticals LLC
- Aurinia Pharmaceuticals Inc
- Aviara Pharmaceuticals Inc
- Avixgen Inc
- AxeroVision Inc
- Azura Ophthalmics Ltd
- Bessor Pharma LLC
- BRIM Biotechnology Inc
- Cambium Medical Technologies LLC
- Cellix Bio Pvt Ltd
- Chong Kun Dang Pharmaceutical Corp
- Dhp Korea Ltd
- Dompe Farmaceutici SpA
- Emerald Bioscience Inc
- EyGen Ltd
- GL Pharm Tech Corp
- Glaukos Corp
- Glia LLC
- HanAll Biopharma Co Ltd
- Huons Co Ltd
- Huons Global Co Ltd
- IACTA Pharmaceuticals Inc
- Icure Pharmaceutical Inc
- Il Dong Pharmaceutical Co Ltd
- Ipsen SA
- IVIEW Therapeutics Inc
- Kala Pharmaceuticals Inc
- Kowa Co Ltd
- Kukje Pharmaceutical Industry Co Ltd
- Kv1.3 Therapeutics
- Laboratoires Thea SA
- Laboratorios Sophia SA de CV
- Lee's Pharmaceutical Holdings Ltd
- LTT Bio-Pharma Co Ltd
- Lubris Biopharma
- Marinomed Biotech AG
- MC2 Therapeutics AS
- Merck & Co Inc
- Mimetogen Pharmaceuticals Inc
- Mitotech SA
- MyX Therapeutics Inc
- Nanomerics Ltd
- Neuroptika Inc
- NicOx SA
- Ningbo Xijian Pharmaceutical Technology Co Ltd
- NovaCell Technology Inc
- Novaliq GmbH
- Novartis AG
- Noveome Biotherapeutics Inc
- OccuRx Pty Ltd
- Ocular Therapeutix Inc
- Oculis SA
- Ocumension Therapeutics (Shanghai) Co Ltd
- Ocunova LLC
- OKYO Pharma Ltd
- OncoNOx ApS
- Oyster Point Pharma Inc
- Palatin Technologies Inc
- Panag Pharma Inc
- Panoptes Pharma GesmbH
- Pharmaleads SA
- Pinotbio Inc
- Pleryon Therapeutics Ltd
- Proteris Biotech Inc
- Protokinetix Inc
- Quorum Innovations LLC
- Redwood Pharma AB
- RegeneRx Biopharmaceuticals Inc
- Reven Pharmaceuticals Inc
- RHNanopharmacuticals LLC
- RiniSight Inc
- Samjin Pharm Co Ltd
- Senju Pharmaceutical Co Ltd
- Serentrix LLC
- Silk Technologies Ltd
- Sol-Gel Technologies Ltd
- Stuart Therapeutics Inc
- Surface Pharmaceuticals Inc
- Sylentis SAU
- Tarsius Pharma Ltd
- TearSolutions LLC
- Tetra Bio-Pharma Inc
- TopiVert Ltd
- Vanda Pharmaceuticals Inc
- Viva Vision Biotech
- Xigen SA
- Yuyu Pharma Inc
